Bożena Jaszczyk

Dr. Bożena Jaszczyk


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LRLeszek Roszkowski
Leszek Roszkowski
BJBożena Jaszczyk
Bożena Jaszczyk
MPMagdalena Plebańczyk
Magdalena Plebańczyk
MCMarzena Ciechomska
Marzena Ciechomska
Rheumatoid arthritis (RA) is an autoimmune chronic inflammatory disease that is still not well understood in terms of its pathogenesis and presents diagnostic and therapeutic challenges. Monocytes are key players in initiating and maintaining inflammation through the production of pro-inflammatory cytokines and S100 proteins in RA. This study aimed to test a specific DNA methylation inhibitor (RG108) and activator (budesonide) in the regulation of pro-inflammatory mediators—especially the S100 proteins. We also searched for new biomarkers of high disease activity in RA patients. RNA sequencing analysis of healthy controls (HCs) and RA monocytes was performed. Genes such as the S100 family, TNF, and IL-8 were validated by qRT-PCR following DNA-methylation-targeted drug treatment in a monocytic THP-1 cell line. The concentrations of the S100A8, S100A11, and S100A12 proteins in the sera and synovial fluids of RA patients were tested and correlated with clinical parameters. We demonstrated that RA monocytes had significantly increased levels of S100A8, S100A9, S100A11, S100A12, MYD88, JAK3, and IQGAP1 and decreased levels of IL10RA and TGIF1 transcripts. In addition, stimulation of THP-1 cells with budesonide statistically reduced the expression of the S100 family, IL-8, and TNF genes. In contrast, THP-1 cells treated with RG108 had increased levels of the S100 family and TNF genes. We also revealed a significant upregulation of S100A8, S100A11, and S100A12 in RA patients, especially in early RA compared to HC sera. In addition, protein levels of S100A8, S100A11, and S100A12 in RA synovial fluids compared to HC sera were significantly increased. Overall, our data suggest that the S100A8 and S100A12 proteins are strongly elevated during ongoing inflammation, so they could be used as a better biomarker of disease activity than CRP. Interestingly, epigenetic drugs can regulate these S100 proteins, suggesting their potential use in targeting RA inflammation.

24 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
JWJakub Wroński
Jakub Wroński
BJBożena Jaszczyk
Bożena Jaszczyk
LRLeszek Roszkowski
Leszek Roszkowski
AFAnna Felis-Giemza
Anna Felis-Giemza
KBKrzysztof Bonek
Krzysztof Bonek
MCMarzena Ciechomska
Marzena Ciechomska
Impaired immunogenicity of COVID-19 vaccinations in inflammatory arthritis (IA) patients results in diminished immunity. However, optimal booster vaccination regimens are still unknown. Therefore, this study aimed to assess the kinetics of humoral and cellular responses in IA patients after the COVID-19 booster. In 29 IA patients and 16 healthy controls (HC), humoral responses (level of IgG antibodies) and cellular responses (IFN-γ production) were assessed before (T0), after 4 weeks (T1), and after more than 6 months (T2) from the booster vaccination with BNT162b2. IA patients, but not HC, showed lower anti-S-IgG concentration and IGRA fold change at T2 compared to T1 (p = 0.026 and p = 0.031). Furthermore, in IA patients the level of cellular response at T2 returned to the pre-booster level (T0). All immunomodulatory drugs, except IL-6 and IL-17 inhibitors for the humoral and IL-17 inhibitors for the cellular response, impaired the immunogenicity of the booster dose at T2. Our study showed impaired kinetics of both humoral and cellular responses after the booster dose of the COVID-19 vaccine in IA patients, which, in the case of cellular response, did not allow the vaccination effect to be maintained for more than 6 months. Repetitive vaccination with subsequent booster doses seems to be necessary for IA patients.

21 September 2026 in Rheumatology International
Verified
Journal Article
Open access
PDF file
AWAnna Wysokińska
Anna Wysokińska
BJBożena Jaszczyk
Bożena Jaszczyk
TSTeresa Sadura-Sieklucka
Teresa Sadura-Sieklucka
Patients with autoimmune and inflammatory diseases most often exhibit sympathetic overactivity and dominance at the expense of the parasympathetic system, including the vagus nerve. It leads to dysfunction of the negative feedback mechanism within the hypothalamic–pituitary–adrenal axis, resulting in impaired regulation of cortisol levels, stress responses, and pro-inflammatory cytokines. Furthermore, vagal dysfunction affects the mechanism by which acetylcholine binds to α7 nicotinic receptors on macrophage surfaces, thereby inhibiting the release of TNF-α and other pro-inflammatory cytokines. The aim of this review was to identify reports elucidating the mechanisms underlying the anti-inflammatory effects of the vagus nerve and to evaluate the efficacy of VNS as a potential method for modulating autonomic nervous system function. A literature search was conducted using the electronic databases PubMed, focusing on the role of the vagus nerve in autoimmune disorders, and on vagus nerve stimulation (VNS). Based on the collected data, a reduction in inflammatory activity and decreased production of pro-inflammatory cytokines were observed following vagus nerve stimulation. Moreover, the authors of the studies analyzed reported additional therapeutic effects, including pain modulation, suppression of disease activity, and a reduction in fatigue. Vagus nerve stimulation represents a promising alternative therapeutic modality for the treatment of rheumatologic diseases. However, further high-quality studies conducted in substantially larger cohorts are required, taking into account variability in stimulation parameters and their differential impact on clinical outcomes.

Verified
Journal Article
Open access
PDF file
BJBożena Jaszczyk
Bożena Jaszczyk
ANAnna Nowakowska-Płaza
Anna Nowakowska-Płaza
BSBarbara Stypińska
Barbara Stypińska
Iwona Sudoł-SzopińskaIwona Sudoł-Szopińska
Iwona Sudoł-Szopińska
BKBrygida Kwiatkowska
Brygida Kwiatkowska
RORobert Olszewski
Robert Olszewski
Objectives: Bone mineral density (BMD) assessment, the gold standard for diagnosing osteoporosis, does not account for bone quality and fracture susceptibility. Trabecular bone score (TBS) adds value to traditional densitometry. No studies have been conducted in the Polish population to date to confirm the association between TBS and fracture occurrence. This study aimed to evaluate the TBS derived from lumbar spine (L1–L4) dual-energy X-ray absorptiometry (DXA) scans in Polish women aged 40–76 years, both with and without osteoporotic fractures. The relationship between TBS, fracture risk (assessed by FRAX and TBS-adjusted FRAX), and BMD at the lumbar spine, femoral neck, and total hip was investigated. Methods: A total of 933 Caucasian women (760 without fracture and 173 with fracture) who underwent DXA examinations (Hologic Discovery A) between 2022 and 2024 were included. Lumbar TBS, BMD, and clinical fracture risk factors were analyzed, excluding subjects with scan artefacts or extreme BMI. Group differences were assessed using t-tests and chi-square tests. Pearson correlation was used to evaluate associations between TBS, age, and BMI. Logistic regression models assessed TBS and BMD as fracture discrimination, and model performance was compared using the Akaike Information Criterion (AIC) and the area under the receiver operating characteristic (ROC) curve (AUC). Results: TBS values were significantly lower in the fracture group (p < 0.001). TBS demonstrated negative correlations with age (r ≈ −0.36) and BMI (r ≈ −0.14). Low TBS values (≤1.23) were associated with the highest fracture prevalence (28.8%) and a threefold increased risk compared to high TBS (odds ratio = 3.0). Each one standard-deviation decrease in BMD or TBS T-score increased fracture risk by 56–67% (both p < 0.001). Models combining TBS and BMD improved discrimination, as indicated by higher AUC and lower AIC, with TBS remaining an independent predictor. In subgroups with osteopenia or osteoporosis, TBS retained statistical significance. Conclusions: TBS combined with BMD effectively discriminates fracture risk in Polish women and offers superior diagnostic accuracy compared to BMD alone. Integrating TBS with BMD enhances fracture accuracy. Routine assessment of TBS may improve clinical management of osteoporosis. Prospective studies are needed to confirm its long-term predictive value.